IRLA IRulya Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662774 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-87.4%
TTM EPS YoY193.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-98.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets26.6%
Debt / equity—
Current ratio14.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.44x
Accruals ratio-55.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $35.38M | $18.59M |
| SG&A expense | $15.05M | $17.58M |
| Operating income | -$58.07M | -$57.28M |
| Pretax income | -$80.77M | -$56.74M |
| Income tax | $3.21M | $87,000 |
| Net income | -$83.98M | -$56.83M |
| EBITDA | -$57.93M | -$57.10M |
| EPS (basic) | -1.68 | -1.31 |
| EPS (diluted) | -1.68 | -1.31 |
| Weighted avg. shares (diluted) | 50.10M | 43.26M |
| Balance sheet | ||
| Cash & equivalents | $5.81M | $6.21M |
| Short-term investments | $11.94M | $34.57M |
| Current assets | $22.90M | $44.04M |
| PP&E, net | $595,000 | $315,000 |
| Goodwill | — | $0 |
| Intangibles | $67.82M | $60.05M |
| Total assets | $93.52M | $114.48M |
| Current liabilities | $43.23M | $7.28M |
| Short-term debt | $18.03M | $0 |
| Long-term debt | $0 | $14.32M |
| Total debt | $18.03M | $14.32M |
| Total liabilities | $129.24M | $84.33M |
| Shareholders' equity | -$35.71M | $30.15M |
| Net debt | $12.22M | $8.11M |
| Shares outstanding | 278,627 | 44.00M |
| Cash flow statement | ||
| Operating cash flow | -$41.42M | -$31.90M |
| Capital expenditure | $352,000 | $257,000 |
| Free cash flow | -$41.78M | -$32.16M |
| Investing cash flow | $23.23M | $21.91M |
| Financing cash flow | $17.91M | -$4.78M |
| Depreciation & amortization | $142,000 | $186,000 |
| Stock-based compensation | $5.11M | $4.75M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.